| The company’s revenue model is built on capital expenditure for the initial system, disposable catheters for each procedure, and annual software licensing fees.
This multi-pronged approach aims to drive recurring revenue and support long-term growth.
Leadership and Vision
Autonomix is led by a proven team with multiple successful exits in the medical technology sector.
The company’s vision is to transform the standard of care for nerve-related disorders by providing physicians with unprecedented visibility and control over neural signaling, thereby improving patient outcomes and quality of life.
This core summary encapsulates Autonomix’s breakthrough technology, clinical validation, market potential, regulatory strategy, and leadership, positioning the company as a leader in the next generation of nerve-targeted therapies.
Grab Sources And More: AMIX Website. AMIX Presentation. -----
And based on a handful of potential catalysts I laid out earlier, (Nasdaq: AMIX) has quickly risen to the top spot on my watchlist. Take a look:
No. 1 AMIX Potential Catalyst - Volatility Potential Could Be Heightened Because Of AMIX's Low Float Structure.
According to info from the Yahoo Finance website, AMIX has a very low float.
The website reports this profile to have roughly 2.4Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential. -----
No. 2 AMIX Potential Catalyst - Two Analyst Targets Suggest Significant Upside Potential (More Than Triple-Digit!)
Two separate analysts are pointing to AMIX as potentially undervalued based on current chart positioning.
Jeffrey S. Cohen of Ladenburg Thalmann Co. Inc. has set an $18 price target for AMIX.
Compared to Thursday’s closing price, this forecast implies a potential upside exceeding 1,250%.
Anthony Vendettii from Maxim Group has also issued a target for AMIX, setting it at $5.00.
From its Thursday close, this price target suggests a potential upside of more than 250% for AMIX. -----
No. 3 AMIX Potential Catalyst - Approval Granted: Potential Addressable Market Could Double As Study Expands.
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain
Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain
Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology
Expansion supports Autonomix’s strategy to build long-term value through multi-indication growth
Patient enrollment expected to begin in June 2025
THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received Ethics Committee authorization from the Ministry of Health of the Republic of Uzbekistan to open the clinical trial site for the follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. The Company is on track to commence enrollment in June 2025.
“This next phase of our clinical program represents a meaningful advancement for Autonomix,” said Brad Hauser, CEO of Autonomix. “With Ethics Committee approval, we can now expand our evaluation beyond severe pancreatic cancer pain to include a broader range of visceral cancers. The initial phase of our study in late-stage pancreatic cancer patients delivered promising results, demonstrating significant pain reduction, substantial decreases in opioid use, and meaningful improvements in quality of life. These outcomes reinforce our belief that Autonomix’s technology has the potential to address multiple cancer indications with significant unmet need and transform the standard of care. As we build on this momentum, we see a clear opp. to create long-term value by unlocking a broader set of impactful clinical applications.”
...
Read the full article here. -----
No. 4 AMIX Potential Catalyst - The Granting Of A Key U.S. Patent Helps Strengthen IP Position.
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology
Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics
Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications
THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,257,071 (‘071 patent) titled Controlled sympathectomy and micro-ablation systems and methods. The newly issued ‘071 patent relates to, but is not necessarily limited to, advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation technologies, providing enhanced precision in treating nerve-related conditions. These systems allow for the identification and ablation of overactive nerves within the peripheral nervous system using a minimally invasive approach. The granted patent represents a significant step forward in Autonomix’s mission to improve patient outcomes by delivering more effective, less invasive treatments for neurological conditions such as chronic pain, hypertension and a myriad of other nerve-related disorders.
“We are excited to announce the issuance of this patent, marking a key milestone in our strategy to transform pain management and treat neurological disorders through minimally invasive, catheter-based denervation. This innovative technology enhances our intellectual property position in the rapidly growing nerve-focused therapeutics space, allowing us to protect our offerings and deliver improved solutions for both clinicians and patients. This patent is a vital addition to our expanding portfolio as we continue working toward our goal of revolutionizing the treatment of nerve-related conditions,” commented Brad Hauser, CEO of Autonomix.
...
Read the full article here. -----
No. 5 AMIX Potential Catalyst - AMIX Reports Positive Outcomes In Key PoC Trial (Tech Could Address Broader Range Of Visceral Cancers).
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain
Initial trial phase (“PoC 1”) achieved key learnings and met all study objectives
Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow-up
Company has initiated market expansion study (“PoC 2”) of additional visceral cancers, and earlier stage pancreatic cancer, to begin in Q2 2025
Additional indications potentially double the addressable market beyond pancreatic cancer pain
THE WOODLANDS, TX, April 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided an update on the initial trial phase of its first-in-human proof-of-concept trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain.
...
Read the full article here. -----
(Nasdaq: AMIX) Recap - These 5 Potential Catalysts Could Earn This Biotech Profile Serious Attention
No. 1 - Volatility Potential Could Be Heightened Because Of AMIX's Low Float Structure.
No. 2 - Two Analyst Targets Suggest Significant Upside Potential (More Than Triple-Digit!)
No. 3 - Approval Granted: Potential Addressable Market Could Double As Study Expands.
No. 4 - The Granting Of A Key U.S. Patent Helps Strengthen IP Position.
No. 5 - AMIX Reports Positive Outcomes In Key PoC Trial (Tech Could Address Broader Range Of Visceral Cancers). -----
Coverage is now officially kicked off on Autonomix Medical, Inc. (Nasdaq: AMIX).
When updates show up, I'll have them out to you quickly. Talk again soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 06/27/2025 and ending on 06/27/2025 to publicly disseminate information about (AMIX:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (AMIX:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/amix-3echr/#details | 
Tidak ada komentar:
Posting Komentar